In recent years it has become apparent that in neuroblastoma ATRX mutations define a distinct patient subgroup that are mutually exclusive with MYCN amplification, associated with older age at diagnosis and a chronic progressive disease course [4,8]. The gene discussed is ATRX; the disease is glycogen storage disease VI.